Telix Pharmaceuticals Ltd
ASX:TLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (183.3), the stock would be worth AU$-3.85 (127% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -690.9 | AU$14.53 |
0%
|
| 3-Year Average | 183.3 | AU$-3.85 |
-127%
|
| Industry Average | 18.9 | AU$-0.4 |
-103%
|
| Country Average | 22.3 | AU$-0.47 |
-103%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
AU$3.4B
|
/ |
Jan 2026
AU$-7.1m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2026
AU$6.6m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2027
AU$54.9m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2028
AU$103.9m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2029
AU$155.7m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2030
AU$374.5m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2031
AU$260m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2032
AU$287.3m
|
= |
|
|
AU$3.4B
|
/ |
Dec 2033
AU$332m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| AU |
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
5B AUD | -690.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 83.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 17.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 30.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.9 |
| Median | 22.3 |
| 70th Percentile | 36.3 |
| Max | 5 709.2 |
Other Multiples
Telix Pharmaceuticals Ltd
Glance View
Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.
